GSK seeks approval for Breo in asthma; Pfizer under fire for event spending;

> GlaxoSmithKline ($GSK) and partner Theravance ($THRX) have U.S. approval to market Breo Ellipta for patients with asthma. Report

> AstraZeneca ($AZN) has filed a lawsuit against Mylan ($MYL) in the U.S. to block a generic version of diabetes drug Onglyza. More

> Bayer has named three employees to new U.S. government relations and external communications roles. Release

> Argentina has approved Sanofi's ($SNY) Lemtrada to treat for multiple sclerosis. Release

> Astellas has appointed Tatjana Dragovic as its VP and regional compliance officer for its Americas region. Report 

> ANI Pharmaceuticals has acquired Lithobid Extended Release tablets from Noven Therapeutics. Release

> The FDA has updated the label of NPS Pharmaceuticals' sole product, Gattex. More

And Finally... Pfizer ($PFE) has agreed to pay a $5,000 fine for failing to report spending on a reception it hosted during the 2012 Democratic National Convention. Story

 

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.